


CLINICAL TRIAL

NCT01367444



Low vision

A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR422459, Administered to Patients With Stargardt's Macular Degeneration

Rare Eye Disease concerned by the trial :
Stargardt's disease

Status of the trial : completed
Orphan drug recognition : N/A

Inclusion criteria : [click here to see detailed criteria](#)

Exclusion criteria : [click here to see detailed criteria](#)



Inclusion
opening date : 15/05/2011



Inclusion closing
date (previsonal) : 15/05/2019

Children



Adults



Within ERN-EYE members



Principal location of the trial :

CHNO des XV XX
28 rue de Charenton
75012 Paris
France

[Contact details](#)




Principal investigator name :

Pr José Alain Sahel



Other investigators :

Dr Saddek Mohand Saïd
Pr Isabelle Audo
CHNO des XV XX



Funder type : Drug company - Industry

[More informations](#)